Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ficlatuzumab plus erlotinib versus placebo plus erlotinib in previously untreated metastatic EGFR-mutated NSCLC with BDX004-positive label
2014-003443-35Phase 2Completed
- Sponsor
- AVEO Oncology
- Start
- Dec 2014
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in non-small cell lung cancer (NSCLC) and EGFR-mutated non-small cell lung cancer comparing Ficlatuzumab + erlotinib with Placebo + erlotinib (2 arms). Primary endpoint: Progression-free survival. Started Dec 2014; status: completed.
02
Drugs
ficlatuzumaberlotinib
03
Conditions
non-small cell lung cancer (NSCLC)EGFR-mutated non-small cell lung cancer
Beyond the preview
Go deeper on 2014-003443-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-003443-35.